Zepbound is the newest GLP-1 medication to be ... A significant difference between these medications is their dosing schedule. Saxenda is typically administered once daily as a subcutaneous ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback